# CytomX Therapeutics, Inc. (CTMX)

> Source: Nexqual · https://nexqual.com/CTMX · data as of 2026-10-28 20:00 UTC · cite as "Nexqual, CytomX Therapeutics, Inc. (CTMX), nexqual.com/CTMX" · informational, not investment advice.

**Price:** USD 2.36 (+2.16% on the day) · last close of Oct 28, 2026; US market pre market, not a live price. Prev close 2.31 · day 2.25–2.39 · 52w 2.16–8.21 · market cap $514M · NMS

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $18.3M, net income -$79.7M (-435.2% margin), free cash flow -$82.5M (SEC filings).
- Insider open-market sales, last ~7 months: 1 Form 4 filings, $5K; 1 not under a Rule 10b5-1 plan ($5K); 0 by opportunistic insiders, 1 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 1.63 on a 1–5 scale) (8 analysts), mean target USD 12.25 (range 6–16).
- Total return with dividends: 1Y -27.6% vs S&P 500 +13.6%; 5Y -60.2% vs S&P 500 +79.8%.
- Next earnings: 2026-11-05, EPS estimate USD -0.07, revenue estimate $10.4M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $37.3M | $53.2M | $101M | $138M | $76.2M | $18.3M |
| Operating income | -$116M | -$101M | -$6.5M | $25.0M | -$22.4M | -$87.2M |
| Net income | -$116M | -$99.3M | -$569K | $31.9M | -$17.4M | -$79.7M |
| Free cash flow | -$121M | -$113M | -$56.9M | -$86.5M | -$75.8M | -$82.5M |
| Operating margin | -311.0% | -190.6% | -6.4% | 18.1% | -29.3% | -476.2% |
| Net margin | -310.5% | -186.8% | -0.6% | 23.1% | -22.8% | -435.2% |
| Revenue growth | -45.5% | +42.5% | +90.4% | +36.4% | -44.8% | — |
| Cash + short-term investments | $266M | $95.6M | $175M | $102M | $137M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 28.1x · P/B 1.7x · FCF yield -16.04% · Earnings yield -15.49%
P/E at fiscal year-ends: Dec 2024 2.7x.

## Insider sales (SEC Form 4, open-market, last ~7 months)
0 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-06-15 | Ogden Christopher | Chief Financial Officer | 1,624 | $5K | 0.5% | No | Routine (sold in Mar each year 2023–2025; this trade is outside those months) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Buy (mean 1.63 on a 1–5 scale), 8 analysts; mean target USD 12.25 (low 6, high 16).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-13 | JP Morgan | Target lowered | Overweight | $12 → $11 |
| 2026-08-10 | Guggenheim | Target lowered | Buy | $15 → $14 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-29) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | -27.6% | -60.2% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | -27.7% | -16.8% |
| Volatility (annualized) | 84.2% | 101.7% |
| Max drawdown | -67.0% (Mar 2026→Oct 2026) | -93.8% (Nov 2021→Mar 2025) |

## Peers (Biotechnology)
ORKA (Oruka Therapeutics, Inc.) USD 95.97 +0.17% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 91.97 -0.23% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.81 +1.58% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.9 +2.14% · AXSM (Axsome Therapeutics, Inc.) USD 143.51 +0.92% · PRAX (Praxis Precision Medicines, Inc) USD 285.48 +6.69%

## More
Full page: https://nexqual.com/CTMX · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.07 | $-0.11 | +$0.03 | $10.4M | 7 |
| Next quarter (ends 2026-12-31) | $-0.10 | $-0.11 | +$0.01 | $5.3M | 7 |
| Current fiscal year (ends 2026-12-31) | $-0.39 | $-0.42 | +$0.03 | $25.0M | 7 |
| Next fiscal year (ends 2027-12-31) | $-0.47 | $-0.49 | +$0.02 | $25.3M | 7 |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$0.09 | −$0.10 | Beat +10.0% | — |
| — | Quarter ended Mar 31, 2026 | −$0.10 | −$0.11 | Beat +9.1% | — |
| — | Quarter ended Dec 31, 2025 | −$0.22 | −$0.09 | Miss −144.4% | — |
| — | Quarter ended Sep 30, 2025 | −$0.09 | −$0.04 | Miss −$0.05 | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

## Recent SEC filings (last 120 days)
| Filed | Form | What it says | Filing |
|---|---|---|---|
| 2026-10-28 | Schedule 13G/A | BANK OF AMERICA CORP /DE/: 5.4% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1501989/000007085826000528/0000070858-26-000528-index.htm |
| 2026-08-14 | Schedule 13G/A | Point72 Asset Management, L.P., Point72 Capital Advisors, Inc.: 3.6% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1501989/000091957426005484/0000919574-26-005484-index.htm |
| 2026-08-14 | Schedule 13G/A | Kynam Capital Management, LP, Kynam Capital Management GP, LLC: 10.0% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1501989/000190788426000014/0001907884-26-000014-index.htm |
| 2026-08-07 | Schedule 13G | STATE STREET CORPORATION: 5.4% of shares, passive 5%+ holder | https://www.sec.gov/Archives/edgar/data/1501989/000009375126000448/0000093751-26-000448-index.htm |
| 2026-08-06 | 8-K | Quarterly results | https://www.sec.gov/Archives/edgar/data/1501989/000119312526338009/0001193125-26-338009-index.htm |
| 2026-08-06 | 10-Q | Quarterly report · period ended Jun 30, 2026 | https://www.sec.gov/Archives/edgar/data/1501989/000119312526337950/0001193125-26-337950-index.htm |
| 2026-08-03 | Schedule 13G | BANK OF AMERICA CORP /DE/: 7.0% of shares, passive 5%+ holder | https://www.sec.gov/Archives/edgar/data/1501989/000007085826000395/0000070858-26-000395-index.htm |
| 2026-07-27 | Schedule 13G | BlackRock, Inc.: 7.6% of shares, passive 5%+ holder | https://www.sec.gov/Archives/edgar/data/1501989/000201238326002247/0002012383-26-002247-index.htm |
| 2026-07-27 | 8-K | Director or executive officer change, or pay arrangement — “On July 24, 2026, Charles Fuchs, M.D., M.P.H., was appointed to the Board of Directors (the "Board") of CytomX Therapeutics, Inc. (the "Company"), effective immediately, as a Class II director, with an initial term expiring at the Company's 2029 annual meeting of stockholders. Dr. Fuchs will receive the Company's standard non-employee director compensation. Upon appointment to the Board, Dr. Fuchs received an option under the Company's 2015 Equity Incentive Plan to purchase 118,000 shares of the Company's common…” | https://www.sec.gov/Archives/edgar/data/1501989/000119312526316929/0001193125-26-316929-index.htm |
Source: SEC EDGAR. Quotes are the opening words of each item as filed.